The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. A link to the full communication detailing information for health care professionals and the Data Summary can be found at <a href="http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm">www.fda.gov/DrugSafetyCommunications</a>. Released 12/20/2017

FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.